背景:以色列在未接种疫苗的孕妇中证实了首例“flurona”-季节性流感(IAV)和SARS-CoV-2的共同感染。这一双重赔偿已在多个国家得到证实,并强调了管理呼吸道病毒性疾病的重要性。
结果:新型结合疫苗是通过加入四种血凝素设计的,三神经氨酸酶,和B细胞表位的四个S蛋白,两种血凝素,三神经氨酸酶,和MHC-I表位的四个S蛋白,和三个血凝素,九神经氨酸酶,和带有接头和佐剂的MHC-II表位的五个S蛋白。发现构建的结合疫苗稳定,无毒,不过敏,和抗原性评分为0.6466。疫苗含有14.87%的α螺旋,29.85%延伸链,9.64%的β转,和45.64%的随机线圈,将其建模为3D结构,在Ramachandran图的最有利区域中具有94.7%的残基,Z评分为-3.33。具有TLR3的疫苗的分子对接代表-1513.9kcal/mol的结合能,具有39个氢键和514个非键合接触,和1.582925e-07的特征值复数。免疫刺激预测表明,结合疫苗可以激活T和B淋巴细胞,产生高水平的Th1细胞因子和抗体。
结论:针对IAV和SARS-CoV-2的计算机设计的疫苗显示出良好的群体覆盖率和免疫应答,具有预测的T细胞和B细胞表位,有利的分子对接,Ramachandran绘图结果,和良好的蛋白质表达。它符合安全标准,表明临床前研究和实验性临床试验的潜力。
BACKGROUND: Israel confirmed the first case of \"flurona\"-a co-infection of seasonal flu (IAV) and SARS-CoV-2 in an unvaccinated pregnant woman. This twindemic has been confirmed in multiple countries and underscores the importance of managing respiratory viral illnesses.
RESULTS: The novel conjugate vaccine was designed by joining four hemagglutinin, three neuraminidase, and four S protein of B-cell epitopes, two hemagglutinin, three neuraminidase, and four S proteins of MHC-I epitopes, and three hemagglutinin, nine neuraminidase, and five S proteins of MHC-II epitopes with linkers and adjuvants. The constructed conjugate vaccine was found stable, non-toxic, non-allergic, and antigenic with 0.6466 scores. The vaccine contained 14.87% alpha helix, 29.85% extended strand, 9.64% beta-turn, and 45.64% random coil, which was modeled to a 3D structure with 94.7% residues in the most favored region of the Ramachandran plot and Z-score of -3.33. The molecular docking of the vaccine with TLR3 represented -1513.9 kcal/mol of binding energy with 39 hydrogen bonds and 514 non-bonded contacts, and 1.582925e-07 of eigenvalue complex. Immune stimulation prediction showed the conjugate vaccine could activate T and B lymphocytes to produce high levels of Th1 cytokines and antibodies.
CONCLUSIONS: The in silico-designed vaccine against IAV and SARS-CoV-2 showed good population coverage and immune response with predicted T- and B-cell epitopes, favorable molecular docking, Ramachandran plot results, and good protein expression. It fulfilled safety criteria, indicating potential for preclinical studies and experimental clinical trials.